Key terms
About RDHL
RedHill Biopharma Ltd. develops medicines for gastrointestinal and infectious diseases. It operates through Commercial Operations, and the Research and Development segments. The Commercial Operations segment covers all areas relating to the commercial sales and is being performed by the subsidiary in the U.S. The Research and Development segment includes the study and licensing of therapeutic candidates. Its products include Talicia, Movantik, and Aemcolo. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest RDHL news
Apr 08
10:27am ET
RedHill Biopharma’s Strategic Pivot and Financial Turnaround
Apr 04
4:57pm ET
RedHill Biopharma Secures $1.25M in Direct Offering
Apr 03
8:00am ET
RedHill Biopharma Announces Securities Sale
Apr 02
7:57am ET
RedHill Biopharma’s Premium Direct Offering
Apr 02
7:04am ET
RedHill Biopharma to sell 2.14M ADSs at 58.289c in registered direct offering
Mar 21
4:57pm ET
RedHill Biopharma Share Capital Increase Approved
Mar 20
5:58pm ET
RedHill Biopharma Reschedules Shareholders Meeting
Mar 11
7:01am ET
RedHill Biopharma announces new USPTO patent covering Talicia through 2034
Mar 05
7:05am ET
RedHill Biopharma’s opaganib to be evaluated by BARDA, NIH
Feb 20
7:13am ET
RedHill Biopharma’s opaganib shows improved lung damage survival in publication
Feb 09
4:23pm ET
RedHill Biopharma files to sell 10.6M American depositary shares for holders
Jan 26
12:48pm ET
RedHill Biopharma announces closing of $8M registered direct offering
Jan 26
11:25am ET
Biotech Alert: Searches spiking for these stocks today
Jan 25
9:07am ET
RedHill Biopharma sells 10M ADSs at 80c in registered direct offering
Jan 25
6:15am ET
RedHill Biopharma announces new USPTO patent grant for Talicia
No recent press releases are available for RDHL
RDHL Financials
Key terms
Ad Feedback
RDHL Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
RDHL Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range